Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)-Reference-Cited by-同舟云学术

Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)

Published:2023-10 Issue:10 Volume:18 Page:1334-1350
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Haratani Koji,Nakamura Atsushi,Mamesaya Nobuaki,Mitsuoka Shigeki,Yoneshima Yasuto,Saito Ryota,Tanizaki Junko,Fujisaka Yasuhito,Hata Akito,Tsuruno Kosuke,Sakamoto Tomohiro,Teraoka Shunsuke,Oki Masahide,Watanabe Hiroshi,Sato Yuki,Nakano Yusuke,Otani Tomoyuki,Sakai Kazuko,Tomida Shuta,Chiba Yasutaka,Ito Akihiko,Nishio Kazuto,Yamamoto Nobuyuki,Nakagawa Kazuhiko,Hayashi Hidetoshi

Funder

AstraZeneca KK

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference60 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Spigel;J Clin Oncol,2022

3. Current challenges of unresectable stage III NSCLC: are we ready to break the glass ceiling of the PACIFIC trial?;Remon;Ther Adv Med Oncol,2022

4. Association of machine learning-based assessment of tumor-infiltrating lymphocytes on standard histologic images with outcomes of immunotherapy in patients with NSCLC;Rakaee;JAMA Oncol,2023

5. Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels;Ricciuti;JAMA Oncol,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer;Future Oncology;2024-07-18

2. Repeated dynamic [18F]FDG PET/CT imaging using a high-sensitivity PET/CT scanner for assessing non-small cell lung cancer patients undergoing induction immuno-chemotherapy followed by hypo-fractionated chemoradiotherapy and consolidative immunotherapy: report from a prospective observational study (GASTO-1067);European Journal of Nuclear Medicine and Molecular Imaging;2024-07-02

3. Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer;British Journal of Cancer;2024-03-22

4. Tumor immunotherapy resistance: Revealing the mechanism of PD-1 / PD-L1-mediated tumor immune escape;Biomedicine & Pharmacotherapy;2024-02

5. Stereotactic body radiation therapy suppresses myeloid-derived suppressor cells by regulating miR-21/Sorbin and SH3 Domain-containing Protein 1 axis;Human & Experimental Toxicology;2024-01